RWE study highlights unmet needs in patients with NSCLC

The analysis included 855 patients with stage III NSCLC, including 475 who presented between 2015 and 2017 and 380 who presented between 2018 and 2019 Results showed that from 2015-2017 to 2018-2019, the proportion of patients undergoing CCRT increased from 34% to 42% “In this real-world setting, only 52% of patients with stage III NSCLC…

Read More

Real-world studies results offer insights for treating EGFR-positive NSCLC

Real-world data can be useful in determining effectiveness in subgroups not included in randomised clinical trials (RCT) RCTs typically focus on a narrow patient population due to rigid exclusion criteria, real-world studies encompass a broader range of patients therefore real-world data can be useful in determining effectiveness in other subgroups “[For] common mutations and patients…

Read More

Real-world data show that filters clean COVID-causing virus from air

The results suggest that air filters could be used to reduce the risk of patients and medical staff contracting SARS-CoV-2 in hospitals, the study’s authors say The study used high-efficiency particulate air (HEPA) filters, which blow air through a fine mesh that catches extremely small particles. The researchers collected air samples from the wards during…

Read More

Cabometyx (cabozantinib) demonstrates real-world survival benefit in advanced renal cell carcinoma

The study analysed outcomes of adults who were diagnosed with stage III or IV RCC between January 1, 2011 and December 31, 2018, with follow-up lasting until January 31, 2020. A total of 440 patients received cabozantinib treatment, while 1045 received axitinib Cabozantinib produced longer survival outcomes than axitinib in patients with advanced RCC that…

Read More